For example, preliminary results of the PRODIGE 24/CCTG PA.6 trial, which were presented at the 2018 ASCO Annual Meeting, demonstrated a significant improvement in overall survival (OS) for patients with resected pancreatic cancer who received adjuvant therapy with a modified FOLFIRINOX regimen (mFOLFIRINOX) versus gemcitabine. Read more . . .
Recent clinical findings across gastrointestinal (GI) cancers addressed unanswered questions in a number of patient populations, said Cathy Eng, MD.